Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURE-01 neoadjuvant pembrolizumab before cystectomy in muscle-invasive bladder cancer
2015-002055-10Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in bladder cancer and muscle-invasive bladder cancer (MIBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic complete response. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2015-002055-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002055-10.